EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma

Olasunkanmi Olaoye iD, Yuan Xiong iD, Cory D Rillahan, Biniam Adane, Giulia DiGiovanni, Kenneth N Ross, Gabriela Alexe, Briana Howard, Nadia Kirmani, Radosław P Nowak iD, Katherine A Donovan, Eric S Fischer iD and 1 more

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00345 ↗

At a glance

Journal article in ACS Chemical Biology, 2026. Written by Olasunkanmi Olaoye and 12 co-authors. Institution: Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, …. Major MEDLINE topics: Histone Deacetylases, Repressor Proteins, Sarcoma, Ewing, Antigens, Nuclear. 53 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, American Cancer Society, National Cancer Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Ewing sarcoma is an aggressive pediatric cancer for which no targeted therapies have been approved. This disease is driven by EWSR1::ETS family fusions that, like most fusion transcription factors, have proven difficult to target directly. Here, we focus on identifying actionable dependencies within the high-risk STAG2-mutant (STAG2-mut) disease subtype of Ewing sarcoma. In STAG2-mut Ewing sarcoma, STAG1 knockout is synthetically lethal but is not readily druggable. Using the Cancer Dependency Map (DepMap), we identify histone deacetylase 8 (HDAC8) as an enriched vulnerability in this molecular context. CRISPR validation and a newly developed HDAC8 degrader, XY-09-36, confirm this selective dependency and suggest increased reliance on HDAC8-mediated cohesin regulation when STAG2 is lost. These findings establish HDAC8 as a context-dependent, pharmacologically accessible vulnerability and outline a framework for discovering rational targets in tumor subtypes where primary drivers are intrinsically hard to drug.

Subjects

MeSH terms (MEDLINE)

Histone DeacetylasesRepressor ProteinsSarcoma, EwingAntigens, NuclearHistone Deacetylase InhibitorsHumansCohesinsCell Cycle ProteinsMutationCell Line, Tumor

Substances

HDAC8 protein, humanHistone DeacetylasesRepressor ProteinsSTAG2 protein, humanCohesinsCell Cycle ProteinsAntigens, NuclearHistone Deacetylase Inhibitors

Authors and institutions

  • Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA02215, USA.
  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA02215, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA02115, USA.
  • Broad Institute of MIT and Harvard , Cambridge, MA02142, USA.

ORCID profiles: Olasunkanmi Olaoye, Yuan Xiong, Radosław P Nowak, Eric S Fischer

Funding

  • NCI NIH HHS
  • American Cancer Society
  • National Cancer Institute
  • National Institutes of Health (NIH)
  • Elsa Pardee Foundation
  • Lubin Family Foundation Fellowship Award

Cite

APA

Olaoye, O., Xiong, Y., Rillahan, C. D., Adane, B., DiGiovanni, G., Ross, K. N., Alexe, G., Howard, B., Kirmani, N., Nowak, R. P., Donovan, K. A., Fischer, E. S., & Stegmaier, K. (2026). Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00345

Vancouver

Olaoye O, Xiong Y, Rillahan CD, Adane B, DiGiovanni G, Ross KN, et al. Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00345

BibTeX
@article{Olaoye2026,
  author = {Olaoye, Olasunkanmi and Xiong, Yuan and Rillahan, Cory D and Adane, Biniam and DiGiovanni, Giulia and Ross, Kenneth N and Alexe, Gabriela and Howard, Briana and Kirmani, Nadia and Nowak, Radosław P and Donovan, Katherine A and Fischer, Eric S and Stegmaier, Kimberly},
  title = {Evaluation of HDAC8 as a Druggable Target in STAG2 -Mutant Ewing Sarcoma},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00345}
}
Start for free →